The two companies have had a relationship since late 2005, when they signedan agreement for the Austrian market - a cooperation that BioGaia presidentPeter Rothschild describes as "successful".
"The launch of BioGaia's products in Germany is important for BioGaia.The German market is big and the potential for our products issignificant" he said.
The launch is expected to take place in 2007 and, as in Austria, theproducts will be available in pharmacies.
BioGaia has been steadily expanding the global reach of its probioticproducts containing its Reuteri bacteria for the last year.
Last week it announced another deal giving Ewopharma the exclusive rightsfor the probiotic chew and oil products sold in pharmacies in Poland, SlovakRepublic, Romania, Bulgaria and Slovenia, as well as Czech Republic andHungary for the chews only (the oils are already marketed in these twocountries under an earlier agreement).
Rothschild told NutraIngredients.com recently that the BioGaia label is seenas preferable, since the company aims to raise awareness of its brand bothamongst consumers and the medical profession, which tends to become aware ofpositive studies first and can recommend the products.
The results of a study investigating the effects of the probiotic bacteriadrops on the symptoms of colic in breast-feeding infants, presented at theEuropean Society for Paediatric Research Meeting in Siena, Italy, lastSeptember, are thought to have boosted interest in Reuteri around the world.
The results of some new studies are expected to be made public in the nearfuture.